Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients. Syed S Mahmood , Peter A Riedell , Stephanie Feldman , Gina George , Stephen A Sansoterra , Thomas Althaus , Mahin Rehman , Elena Mead , Jennifer E Liu , Richard B Devereux , Jonathan W Weinsaft , Jiwon Kim , Lauren Balkan , Tarek Barbar , Katherine Lee Chuy , Bhisham Harchandani , Miguel-Angel Perales , Mark B Geyer , Jae H Park , M Lia Palomba , Roni Shouval , Ana A Tomas , Gunjan L Shah , Eric H Yang , Daria L Gaut , Michael V Rothberg , Evelyn M Horn , John P Leonard , Koen Van Besien , Matthew J Frigault , Zhengming Chen , Bhoomi Mehrotra , Tomas G Neilan , Richard M Steingart European heart journal（2023）
摘要
Chimeric antigen receptor T-cell therapy recipients who experience SCE have higher overall mortality and NRM and higher peak levels of IL-6, CRP, ferritin, and troponin.
更多 查看译文
关键词
CAR-T cells, Cancer, Cardio-oncology, Cardiovascular events, Chimeric antigen receptor, Mortality
AI 理解论文
溯源树
样例
